Watson has resumed shipments of INFeD (iron dextran injection), an intravenous iron replacement therapy for the treatment of patients with documented iron deficiency anemia in whom oral administration is unsatisfactory or impossible. The product had been out of stock due to changes in the final product manufacturing site and issues with raw material supply. Watson expects to be in a normal supply situation for INFeD shortly.

For more information call (800) 272-5525 or visit www.watson.com.